ProPhase Labs, Inc. (PRPH)
- Previous Close
5.0600 - Open
5.0600 - Bid 4.8100 x 100
- Ask 5.1100 x 100
- Day's Range
4.9000 - 5.1150 - 52 Week Range
4.0500 - 9.9400 - Volume
12,023 - Avg. Volume
51,467 - Market Cap (intraday)
89.324M - Beta (5Y Monthly) -0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 24, 2022
- 1y Target Est
21.00
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
www.prophaselabs.com113
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRPH
Performance Overview: PRPH
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRPH
Valuation Measures
Market Cap
89.32M
Enterprise Value
105.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.92
Price/Book (mrq)
1.81
Enterprise Value/Revenue
2.39
Enterprise Value/EBITDA
-7.15
Financial Highlights
Profitability and Income Statement
Profit Margin
-37.81%
Return on Assets (ttm)
-15.05%
Return on Equity (ttm)
-29.70%
Revenue (ttm)
44.38M
Net Income Avi to Common (ttm)
-16.78M
Diluted EPS (ttm)
-0.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
4.74M
Total Debt/Equity (mrq)
43.29%
Levered Free Cash Flow (ttm)
-4.26M